Democritus University of Thrace (DUTH)
Πειραματική διερεύνηση της επίδρασης της σιμβαστατίνης (HGM-CoA reductase inhibitors) στον μηχανισμό πώρωσης των καταγμάτων
Abstract
dc:descriptionIntroduction: Bone loss diseases, including osteoporosis, remain a major public health problem in all Western communities. Several years ago, Mundy et al. during a search for non-toxic agents that enhance osteoblast differentiation and bone formation, found that statins (the widely used lipid-lowering hydroxymethylglutaryl-coenzyme A reductase inhibitors) could have an anabolic effect on bone formation both in vitro and in vivo by activation of the promoter of the Bone Morphogenetic Protein-2 (BMP-2) gene. More specifically, simvastatin doses from 1 to 10 mg/kg/day were found to enhance bone formation and trabecular volume on intact bones of rodents. Several observational and experimental studies followed that designated the beneficial effect of simvastatin on bone turnover pa-rameters and on reduction of the fracture risk. On the contrary, other authors failed to produce a clear anabolic effect on bone formation by the administration of statins. Until recently, a large number of series have investigated the potential skeletal effects of statins on undisturbed bone but only a few re-cent studies have examined their effects on fracture healing. Skoglund et al, studied the systemic ad-ministration of simvastatin in mice in extremely high doses (of 120 mg/kg/day) and recorded that frac-ture healing was enhanced, without though, interest on any major side effects or complications such as liver failure, rhabdomyolisis and myopathy from that exceedingly high dose. The authors concluded that additional studies with lower doses and different species are needed to establish this effect. Objectives: The purpose of this study is to investigate any potential early effect of the systemic ad-ministration of simvastatin in low doses (based on earlier safety and efficacy studies on undisturbed bone) on fracture healing, using a well-established fracture healing model. Materials-methods: Fifty-four skeletally mature male New Zealand White rabbits were used for the study. The rabbits were assigned to one of three experimental groups: a control group, and two groups that were orally administrated a diet with 10 and 30 mg/kg/day of simvastatin, respectively. A com-plete biochemical blood count was performed to exclude drug-induced complications. Half of the ani-mals of each group were sacrificed at 15 days and the other half at 30 days after surgery at which time intervals healing quality was assessed. The bones were subjected to biomechanical testing, histomor-phometric analysis and peripheral quantitative computed tomography. Results: In animals received simvastatin of 30 mg/ kg/day a significant reduction of BMD and callus stiffness were observed. At 15 days, the amount of cartilaginous callus formation was reduced, and the void space was significantly increased, in the animals of both groups that received simvastatin when compared to the control group (p < .05). Conclusions: Our study suggest that simvastatin doses of 30 mg/kg/day may have a negative anabol-ic effect on callus formation in rabbits, whereas doses of 10 mg/kg/day seem not to produce any sig-nificant positive or a negative effect, especially at the early stages of fracture remodeling.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chissas, Dionysios
- Χίσσας, Διονύσιος
Subjects
dc:subject × 25- Σιμβαστατίνη
- Κατάγματα
- Αναβολική δράση σιμβαστατίνης
- Πώρωση καταγμάτων
- Στατίνες
- Οστικός μεταβολισμός
- Συστηματική χορήγηση σιμβαστατίνης
- Πειραματική μελέτη σε κονίκλους
- Οστική ανακατασκευή
- Επιπλοκές από υψηλές δόσεις στατινών
- Simvastatin
- Fractures
- Experimental study in rabbits
- Skeletal effect of statins
- Oral administration of simvastatin
- Fracture healing
- Anabolic effect of simvastatin
- Callus formation
- Simvastatin dosage
- Toxicity
- Hydroxymethylglutary-coenzyme A reductase inhibitors
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26101